Back to Interventions

Substance / Medication

Ibutilide

SNOMED 372500009 UMLS C0082966

Overview

Active Ingredient

ibutilide

RxNorm CUI

41289

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Conduction disorder of the heart

Atrial fibrillation

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

LOINC 2093-3

secondary

C reactive protein

LOINC 30522-7

primary

Clinical Trials

4 trials linked to this intervention

4

Total Trials

0

Recruiting

2

With Results

Recent Trials

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

NCT03834883Phase 4Completed27 enrolled

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788Phase 4Completed73 enrolled

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940Phase 4Completed14 enrolled

Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

NCT01447862Phase 4Completed101 enrolled

View all 4 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Clinical and electrophysiologic effects of calcium channel blockers in patients receiving ibutilide.

Wood Mark A, Gilligan David M, Brown-Mahoney Chris et al. · Am Heart J · 2002

PMID: 11773930Meta-Analysis

Comparison of Direct Current Synchronized Cardioversion to Ibutilide-Guided Catheter Ablation for Long-Term Sinus Rhythm Maintenance After Isolated Pulmonary Vein Isolation of Persistent Atrial Fibrillation.

Wang Maojing, Zhao Qing, Ding Wei et al. · Am J Cardiol · 2017

PMID: 28501100RCT

Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.

Simon Alexander, Niederdoeckl Jan, Skyllouriotis Ekaterini et al. · Europace · 2017

PMID: 28175295RCTFull text (PMC)

The modified stepwise ablation guided by low-dose ibutilide in chronic atrial fibrillation trial (The MAGIC-AF Study).

Singh Sheldon M, d'Avila Andre, Kim Young-Hoon et al. · Eur Heart J · 2016

PMID: 26850076RCT

[Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter].

Yu Zhong, Xiang Meixiang, Ma Changsheng et al. · Zhejiang Da Xue Xue Bao Yi Xue Ban · 2013

PMID: 23585009RCT

Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.

Patsilinakos Sotirios, Christou Apostolos, Kafkas Nikolaos et al. · Am J Cardiol · 2010

PMID: 20723644RCT

Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter.

Steinwender Clemens, Hönig Simon, Kypta Alexander et al. · Int J Cardiol · 2010

PMID: 19136164RCT

Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate.

Fragakis Nikolaos, Bikias Athanasios, Delithanasis Ioannis et al. · Europace · 2009

PMID: 18987127RCT

Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter.

Tercius Alix J, Kluger Jeffrey, Coleman Craig I et al. · Pacing Clin Electrophysiol · 2007

PMID: 17976094RCT

Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.

Korantzopoulos P, Kolettis T M, Papathanasiou A et al. · Heart · 2006

PMID: 16159973RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Cardiovascular Disease Physician

Internal Medicine — Cardiovascular Disease

NUCC 207RC0000X

Clinical Cardiac Electrophysiology Physician

Internal Medicine — Clinical Cardiac Electrophysiology

NUCC 207RC0001X

Find a Provider

Health Goals

Goals connected through associated conditions

Improve Heart Health

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ibutilide (substance)
SNOMED CT: 372500009
UMLS CUI: C0082966
RxNorm CUI: 41289

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

4

Conditions

2

Biomarkers

2

Specialists

0

Symptoms

4

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.